Abstracts tagged "Scleroderma, Systemic"

Abstract Number: 0413 • ACR Convergence 2021
Predictors of ILD Development and Timing of Onset in Systemic Sclerosis: A Canadian Cohort
Jessica Kapralik, Robert Morton, Malik Farooqi, Karen Beattie, Nathan Hambly and Maggie Larche, McMaster University, Hamilton, ON, Canada
Background/Purpose: In patients with SSc, interstitial lung disease (SSc-ILD) and pulmonary hypertension affect 50-70% of patients and are the leading cause of death. Recent trials…
Abstract Number: 1379 • ACR Convergence 2021
Serum Levels of the Soluble Receptor for Advanced Glycation Endproducts Are Prospectively Associated with Pulmonary Arterial Hypertension in Systemic Sclerosis
Isabella Atzeni¹, Yehya Al-Adwi², Berber Doornbos-van der Meer², Anniek Van Roon², Caroline Roozendaal¹, Andries Smit², Alja J. Stel², Harry Van Goor², Tji-Joong Gan¹, Johanna Westra² and Douwe J Mulder², ¹University of Groningen, University Medical Centre Groningen, Groningen, Groningen, Netherlands, ²University of Groningen, University Medical Centre Groningen, Groningen, Netherlands
Background/Purpose: Interstitial lung disease (ILD) and pulmonary arterial hypertension (PAH) are the leading causes of death in Systemic Sclerosis (SSc). Markers for early detection of…
Abstract Number: 0500 • ACR Convergence 2021
Clinical Phenotypes of Patients with Systemic Sclerosis with Distinct Molecular Signatures in the Skin
Monica Yang¹, Vivien Goh², Monica Espinoza³, Yiwei Yuan⁴, Julia Lee⁵, Mary Carns⁶, Dinesh Khanna⁷, Zsuzsanna McMahan⁸, Michael Whitfield⁹ and Monique Hinchcliff¹⁰, ¹University of California San Francisco, San Francisco, CA, ²Northwestern University, Chicago, IL, ³Geisel School of Medicine, Hanover, NH, ⁴Dartmouth College, Hanover, NH, ⁵Northwestern University Feinberg School of Medicine, Chicago, IL, ⁶Northwestern University Division of Rheumatology, Chicago, IL, ⁷University of Michigan, Ann Arbor, MI, ⁸Johns Hopkins Rheumatology, Baltimore, MD, ⁹Geisel School of Medicine, Lebanon, NH, ¹⁰Yale School of Medicine, Westport, CT
Background/Purpose: Although two subsets in systemic sclerosis (SSc) have been identified based on degree of skin disease, the current classification system, limited vs. diffuse cutaneous,…
Abstract Number: 1382 • ACR Convergence 2021
Survey on Treatment Practices in Subclinical Interstitial Lung Disease in Systemic Sclerosis
Sabrina Hoa¹, Murray Baron² and Marie Hudson³, ¹Division of Rheumatology, Centre hospitalier de l'Université de Montréal; Department of Medicine, Université de Montréal, Montréal, QC, Canada, ²Jewish General Hospital, Montréal, QC, Canada, ³McGill University, Montréal, QC, Canada
Background/Purpose: Interstitial lung disease (ILD) is a leading cause of mortality in systemic sclerosis (SSc). Early detection and treatment of SSc-ILD may lead to improved…
Abstract Number: 0541 • ACR Convergence 2021
N-formyl Methionine Peptide-mediated Neutrophil Activation in Systemic Sclerosis
Runa Kuley¹, Ryan Stultz², Bhargavi Duvvuri², Roger Hesselstrand³, J Lee Nelson⁴ and Christian Lood², ¹Division of Rheumatology, University of Washington, Seattle, WA, ²University of Washington, Seattle, WA, ³Lund University, Lund, Sweden, ⁴Fred Hutchinson Cancer Research Center, University of Washington, Seattle, WA
Background/Purpose: Systemic sclerosis (SSc) is a complex systemic autoimmune disease, and its etiology is unknown. Exaggerated neutrophil activation and formation of neutrophil extracellular traps (NETs)…
Abstract Number: 1383 • ACR Convergence 2021
Prediction of Digital Ulcers in Patients with Systemic Sclerosis Based on the Use of Platelet Inhibitors and Other Parameters – A EUSTAR Study on Derivation and Validation of a Clinical Prediction Model
Alexandru Garaiman¹, Klaus Steigmiller², Catherine Gebhard³, Marco Matucci-Cerinic⁴, Jorg Henes⁵, Jeska de Vries-Bouwstra⁶, Vanessa Smith⁷, Andrea Doria⁸, Yannick Allanore⁹, Lorenzo Dagna¹⁰, Branimir Anic¹¹, Carlomaurizio Montecucco¹², Otylia Kowal-Bielecka¹³, Mickael Martin¹⁴, Yoshiya Tanaka¹⁵, Anna-Maria Hoffmann-Vold¹⁶, Ulrike Held², Oliver Distler¹⁷ and Mike Oliver Becker¹⁸, ¹University Hospital Zurich, University of Zurich, Zurich, Switzerland, ²Epidemiology, Biostatistics and Prevention Institute, Department of Biostatistics, University of Zurich, Zurich, Switzerland, ³Department of Nuclear Medicine, University Hospital Zurich, University of Zurich, Zurich, Switzerland, ⁴University of Florence, Florence, Italy, ⁵University Hospital Tuebingen, Tuebingen, Germany, ⁶Leiden University Medical Center, Leiden, Netherlands, ⁷Department of Rheumatology and Internal Medicine, Ghent University Hospital, Ghent, Belgium, ⁸University of Padova, Padova, Italy, ⁹Université de Paris, Paris, France, ¹⁰10Unit of Immunology, Rheumatology, Allergy and Rare Diseases (UnIRAR), IRCCS San Raffaele Scientific Institute, Milano, Italy, ¹¹Division of Clinical Immunology and Rheumatology, Department of Internal Medicine, University Hospital Centre Zagreb and University of Zagreb, School of Medicine, Zagreb, Croatia, ¹²Department of Rheumatology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy, ¹³Department of Rheumatology and Internal Medicine, Medical University of Bialystok, Bialystok, Poland, ¹⁴Internal Medicine, Poitiers University Hospital, Poitiers, France, ¹⁵University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁶Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ¹⁷Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich/University of Zurich, Zurich, Switzerland, ¹⁸Department of Rheumatology, University Hospital Zurich, University of Zurich, Zurich, Switzerland
Background/Purpose: Digital ulcers (DUs) affect half of the patients with systemic sclerosis (SSc) and can be complicated by gangrene and amputation. Platelets are known to…
Abstract Number: 0544 • ACR Convergence 2021
Targeting CD13/aminopeptidase N as a Novel Therapeutic Approach for Scleroderma Fibrosis
Eliza Pei-Suen Tsou, M.Asif Amin, Phillip Campbell, Mikel Gurrea-Rubio, Morgan Omara, Ellen Model, Pamela Palisoc, Mustafa Ali, Sirapa Vichaikul, Jonatan Hervoso, Jeffrey Ruth, Dinesh Khanna and David Fox, University of Michigan, Ann Arbor, MI
Background/Purpose: Aminopeptidase N, also known as CD13, is a Zn2+-dependent membrane bound ectopeptidase widely expressed in mammalian cells including rheumatoid arthritis (RA) fibroblast-like synoviocytes (FLS),…
Abstract Number: 1389 • ACR Convergence 2021
Subclinical ILD Is Frequent and Progresses Across Different Connective Tissue Diseases
Anna-Maria Hoffmann-Vold¹, Helena Andersson², Silje Reiseter², Håvard Fretheim², Imon Barua¹, Torhild Garen³, Øyvind Midtvedt¹, Ragnar Gunnarsson², Michael Durheim², Trond Mogens AAløkken² and Øyvind Molberg¹, ¹Department of Rheumatology, Oslo University Hospital, Oslo, Norway, ²Oslo University Hospital, Oslo, Norway, ³Department of Rheumatology, Oslo University Hospital, Oslo, Nepal
Background/Purpose: Based on the argument that symptoms-define-disease, physicians commonly apply the terms pre-clinical or sub-clinical disease to describe patients with disease-related findings, but no accompanying…
Abstract Number: 0545 • ACR Convergence 2021
SIRT1 Modulates the Senescent Phenotype in Scleroderma Endothelial Cells
Ellen Model, Morgan Omara, Pamela Palisoc, Dinesh Khanna and Eliza Pei-Suen Tsou, University of Michigan, Ann Arbor, MI
Background/Purpose: Vascular abnormalities in systemic sclerosis (SSc) are characterized by injury to vascular wall and extensive damage of the microvessels. It has been shown that…
Abstract Number: 1390 • ACR Convergence 2021
A 5% Increase in Interstitial Lung Disease at 1-Year Follow-up Is Associated with Long-Term ILD Progression in Systemic Sclerosis
Alicia Hinze¹, Shreyasee Amin¹, Ashima Makol¹, Robert Vassallo¹, Cynthia Crowson² and Brian Bartholmai¹, ¹Mayo Clinic, Rochester, MN, ²Mayo Clinic, Eyota, MN
Background/Purpose: The clinical course of interstitial lung disease (ILD) in systemic sclerosis (SSc) is highly variable. Some patients experience a progressive decline in lung function…
Abstract Number: 0933 • ACR Convergence 2020
Advanced Multiparametric Magnetic Resonance Imaging of Muscle for Detection and Quantification of Muscle Disease in Systemic Sclerosis
Julie Paik¹, Fredrick Wigley², Laura Fayad³, Laura Hummers⁴ and Michael Jacobs¹, ¹Johns Hopkins University, Baltimore, MD, ²Johns Hopkins University School of Medicine, Baltimore, MD, ³Joh, Baltimore, MD, ⁴Johns Hopkins Univerisity, Ellicott City, MD
Background/Purpose: Skeletal myopathy in systemic sclerosis (SSc) is underappreciated yet an important manifestation of SSc. While it has been reported that there are distinct histopathologic…
Abstract Number: 1910 • ACR Convergence 2020
Integrated Molecular Analysis of Systemic Sclerosis Skin and Blood Highlights Significant Differences Between Major Autoantibody Subgroups
Kristina Clark¹, Corrado Campochiaro², Eszter Csomor³, Adam Taylor³, Katherine Nevin³, Nicholas Galwey³, Mary Morse³, Voon Ong⁴, Emma Derrett-Smith⁵, Shaun Flint³ and Christopher Denton¹, ¹University College London, London, United Kingdom, ²Royal Free Hospital NHS trust, London, United Kingdom, ³GlaxoSmithKline, Stevenage, United Kingdom, ⁴UCL, London, United Kingdom, ⁵University College London Division of Medicine, London, United Kingdom
Background/Purpose: The major antinuclear autoantibodies of systemic sclerosis (SSc) associate with different skin score trajectories and risk of internal organ manifestations. To elucidate molecular differences…
Abstract Number: 1052 • ACR Convergence 2020
Connective Tissue Disease-Related Interstitial Lung Disease in American Indian/Alaska Native People in Alaska
Joanna Marco¹ and Elizabeth Ferucci², ¹University of Washington, Seattle, WA, ²Alaska Native Tribal Health Consortium, Anchorage, AK
Background/Purpose: Many connective tissue diseases are known to cause interstitial lung disease (ILD). American Indian/Alaska Native (AI/AN) populations have higher prevalence and severity of a…
Abstract Number: 2034 • ACR Convergence 2020
Resolving Phenotypic and Prognostic Differences in Interstitial Lung Disease Related to Systemic Sclerosis by Computed Tomography-based Radiomics
Janine Schniering¹, Malgorzata Maciukiewicz¹, Hubert Gabrys², Matthias Brunner¹, Christian Blütghen³, Chantal Meier¹, Sophie Braga-Lagache⁴, Anne-Christine Ulgry⁴, Manfred Heller⁴, Oliver Distler¹, Matthias Guckenberger², Havard Fretheim⁵, Anna-Maria Hoffmann-Vold⁵, Christos Nakas⁶, Thomas Frauenfelder³, Stephanie Tanadini-Lang² and Britta Maurer⁷, ¹Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ²Department of Radiation Oncology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ³Institute of Diagnostic and Interventional Radiology, University Hospital Zurich, Switzerland, Zurich, Switzerland, ⁴Proteomics and Mass Spectrometry Core Facility, Department for BioMedical Research (DBMR), University of Bern, Switzerland, Bern, Switzerland, ⁵Department of Rheumatology, Oslo University Hospital, and Institute of Clinical Medicine, University of Oslo, Norway, Oslo, Norway, ⁶Laboratory of Biometry, University of Thessaly, Volos, Greece, Volos, Greece, ⁷Center of Experimental Rheumatology, Department of Rheumatology, University Hospital Zurich, Switzerland, Zurich
Background/Purpose: Radiomics describes the in-depth analysis of tissue phenotypes by computational retrieval of high-dimensional quantitative imaging features including tissue intensity, texture, and wavelet characteristics. Here,…
Abstract Number: 1069 • ACR Convergence 2020
Scleromyositis Is Associated with Nailfold Capillary Abnormalities Compared to Immune-Mediated Necrotizing Myopathy
Océane Landon-Cardinal¹, Valérie Leclair², Yves Troyanov³, Martial Koenig⁴, Alain Meyer⁵, Sabrina Hoa¹, Josiane Bourré-Tessier¹, Isabelle Ferdinand⁶, Jason Karamchandani⁷, Erin O'Ferrall⁸, Minoru Satoh⁹, Marvin Fritzler¹⁰, Benjamin Ellezam¹¹, Jean-Luc Senécal¹, Marie Hudson² and Geneviève Gyger², ¹Division of Rheumatology, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ²Division of Rheumatology, Jewish General Hospital, Montréal, QC, Canada, ³Division of Rheumatology, Hôpital du Sacré-Coeur, Montréal, QC, Canada, ⁴Division of Internal Medicine, Centre hospitalier de l'Université de Montréal, Montréal, QC, Canada, ⁵Service de rhumatologie et Centre de références des maladies autoimmunes rares, Hôpitaux universitaires de Strasbourg, Strasbourg, Alsace, France, ⁶Institut de Rhumatologie de Montréal, Montréal, QC, Canada, ⁷Department of Pathology, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁸Department of Neurology and Neurosurgery, Montreal Neurological Institute and Hospital, Montreal, QC, Canada, ⁹Department of Clinical Nursing, University of Occupational and Environmental Health, Kitakyushu, Japan, ¹⁰Department of Medicine, Cumming School of Medicine, University of Calgary, Calgary, AB, Canada, ¹¹Division of Pathology, Centre hospitalier universitaire Sainte-Justine, Montréal, QC, Canada
Background/Purpose: Scleromyositis (SM) is an emerging subgroup of autoimmune myositis associated with features of systemic sclerosis (SSc) and characterized by prominent vasculopathic features on ultrastructural…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].